Business Context and Reporting Period
Company: Nanophase Technologies Corporation (Note: Input metadata listed "SOLESENCE, INC." but the filing text identifies the registrant as Nanophase Technologies Corporation).
Reporting Period: Fiscal year ended December 31, 2002.
Business Overview: Nanophase engineers and manufactures nanocrystalline materials for commercial applications, primarily in sunscreens, personal care, automotive catalytic converters, and electronics polishing (Chemical Mechanical Planarization or CMP). The company operates production facilities in Romeoville and Burr Ridge, Illinois.
Key Financial Metrics (Year Ended Dec 31, 2002)
| Metric | 2002 | 2001 |
|---|---|---|
| Total Revenue | $5,401,215 | $4,055,488 |
| Product Revenue | $5,002,986 | $3,650,914 |
| Cost of Revenue | $5,095,019 | $4,906,716 |
| Gross Profit | $306,196 | ($851,228) |
| Operating Loss | ($5,120,852) | ($6,251,442) |
| Net Loss | ($5,155,237) | ($5,740,243) |
| Net Loss Per Share (Basic/Diluted) | ($0.35) | ($0.42) |
| Cash and Cash Equivalents | $445,684 | $582,579 |
| Total Investments | $7,062,808 | $6,842,956 |
| Total Liquidity (Cash + Investments) | $7,508,492 | $7,425,535 |
| Working Capital | $7,380,051 | $7,215,520 |
| Long-Term Debt | $364,563 | $812,390 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 33% to $5.4 million, driven by a 29% increase in product sales from the largest customer (BASF) and growth in the CMP market.
- Gross Margin Improvement: The company achieved a positive gross profit of $306,196 (5.7% margin) in 2002, compared to a gross loss of $851,228 in 2001. This was due to increased sales volume, operating efficiencies, and a reduction in inventory write-downs.
- Operating Expenses: Operating loss narrowed by approximately $1.1 million. Research and Development (R&D) expenses decreased slightly to $1.57 million, while Selling, General, and Administrative (SG&A) expenses increased to $3.85 million due to executive hiring and legal costs.
- Financing Activity: In May 2002, the company completed a private placement of 1.37 million shares, raising net proceeds of approximately $6.2 million to fund growth and working capital.
- Interest Income: Decreased significantly to $152,626 from $585,782 in 2001 due to lower average funds available for investment and reduced yields.
Guidance, Outlook, Risks, and Contingencies
- Liquidity Covenants: The supply agreement with the largest customer (BASF) contains financial covenants requiring the company to maintain at least $2.0 million in cash and investments and no more than $10.0 million in debt. Failure to meet these could trigger a transfer of technology and equipment to the customer. As of Dec 31, 2002, the company held $7.5 million in liquidity and debt under $2.0 million, meeting these requirements.
- Customer Concentration: Revenue is heavily concentrated; BASF and C.I. Kasei (CIK) accounted for 72.6% and 6.8% of 2002 revenue, respectively. Loss of a key customer would have a material adverse effect.
- Legal Proceedings:
- Harbour Court LPI: Settled for $800,000 (funded by insurance) in January 2002.
- George Tatz: A class action lawsuit alleging securities fraud regarding revenue booking with a customer named Celox is ongoing. The court denied the company's motion to dismiss in October 2002. The outcome is uncertain and could be material.
- Outlook: Management expects capital spending in 2003 to be approximately $525,000. The company believes current cash and investment balances are sufficient to fund operations for the next twelve months.
- Unusual Items: In 2002, the company recognized a $10,000 contribution to gross profit from the sale of inventory for which an allowance had previously been recorded. In 2001, a $539,415 inventory write-down related to a catalyst customer significantly impacted margins.
Investor Verification Checklist
- Covenant Compliance: Verify that cash and investment balances remain above the $2.0 million threshold required by the BASF supply agreement to prevent technology transfer.
- Customer Concentration: Monitor the stability of the relationship with BASF, which represents nearly 73% of revenue.
- Litigation Status: Track the progress of the George Tatz class action lawsuit regarding the Celox revenue booking allegations.
- Inventory Valuation: Review the allowance for excess inventory quantities ($657,264 at year-end) to assess potential future write-downs.
- Capital Requirements: Assess the sufficiency of the $7.5 million liquidity position against the projected $525,000 capital spend and ongoing operating losses.